Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SMC Ltd. is a well-established, global contract manufacturer serving the medical technology and pharmaceutical industries. It offers a comprehensive suite of services including device design, engineering, injection molding, assembly, sterile filling, analytical services, and supply chain management. The company leverages its proprietary autoinjector platforms and extensive regulatory expertise to help clients accelerate product development and commercialization. With a significant international footprint, SMC is positioned as a strategic manufacturing partner for healthcare innovators seeking scalable, risk-mitigated production solutions.

Medical DevicesDrug Delivery

Technology Platform

Proprietary autoinjector platforms (ArQ, Vita Devices) for drug delivery, integrated with capabilities in silicone injection molding, device design/engineering, sterile fill-finish, and analytical services for combination products.

Opportunities

Growth is driven by the strong trend toward outsourcing in pharma/medtech, the rapid expansion of the biologics and combination product market requiring advanced delivery devices, and the increasing demand for point-of-care diagnostic kits.
SMC's integrated device-and-drug service model is ideally positioned to capture this convergence.

Risk Factors

Key risks include dependence on key client contracts, operational risks related to sterile manufacturing and quality compliance, vulnerability to global supply chain disruptions, and intense competition in the CMO space which could pressure pricing and margins.

Competitive Landscape

SMC competes in the fragmented but competitive global Contract Manufacturing Organization (CMO) market for medical devices and pharma services. Competitors range from large, diversified CMOs (e.g., Lonza, Catalent for pharma services; Flex, Jabil for devices) to smaller, niche specialists. SMC differentiates through its deep focus on complex single-use devices, proprietary autoinjector platforms, and an integrated 'device through drug product' offering for combination products.